ARI-1778 - AbbVie, Arisaph
Preclinical evaluation of Rev D-4F for the treatment of atherosclerosis (Abbott) - Jul 1, 2012 - Preclinical evaluation of Rev D-4F for the treatment of atherosclerosis 
Preclinical • Dyslipidemia
http://www.arisaph.com/randd/
 
Jul 1, 2012
 
ARI 1778, KH 01503, Rev D-4F, Reverse D-4F